Jason Karlawish

speaker

1,378 appearances 5 recordings 1 series first heard Feb 2021 last heard Dec 2023

Jason Karlawish’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

No recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.

Appearances

newest first · ▶ plays the moment

GeriPal - A Geriatrics and Palliative Medicine Podcast · Amyloid Antibodies and the Role of the Geriatrician: Nate Chin, Sharon Brangman, and Jason Karlawish · 17 Aug 2023 podcast

I I haven't quite answered your question, but I I I think that the data are seen

You can look at who dropped out or who discontinued throughout.

But the data on the primary endpoints are all comers, everyone in the stud.

So certainly

I mean I want to hear what I mean what what go ahead, Sharon.

And let's so w this drug up front is a bit of work.

You know, MRIs prior, genetic testing prior.

Pocketive assessment, amyloid testing prior, and then a schedule of MRIs following.

if it's then if it's Lacanomab, it's Q two week infusion.

If it's um denanomab, it's every month infusion.

So it's a bit of work.

Um I you know, for example, it pretty much says you need someone else because you gotta get in there to get the infusions and whatnot.

I'd be very reluctant to prescribe it to someone who

I don't know what it means to live alone, but who didn't have anyone around them to watch over and whatnot, given the side effects of RA and the upfront infusion.

So it's I agree that the drugs a lot of work.

Um I personally don't have a strict age cutoff based on the eligibility criteria.

I will say that on my geriatrics colleagues, um, anyone coming in with

cognitive impairment that's incipient occurred in the last several years, who's seventy five, eighty, eighty five plus, think about late, T D P forty three.

Showing 261–280 of 1,378 · page 14 of 69